脑胶质瘤诊疗关键技术创新与推广应用——2017年度国家科学技术进步二等奖

doi:10.3969/j.issn.1006-7795.2018.01.001

摘要/Abstract

摘要： 脑胶质瘤是颅内最常见的原发恶性肿瘤。由于发病部位特殊，脑胶质瘤手术致残率高，癫痫发生率高；由于异质性强，术后化学药物治疗敏感性不一，存活率低，是全球难治性肿瘤之一。江涛教授项目组从构建中国人群脑胶质瘤多维组学公共数据平台入手，制定出中国人脑胶质瘤分子分型新标准，建立了脑胶质瘤个体化分子诊疗与精准化手术技术体系，使脑功能区胶质瘤全切率提高到67%，术后长期功能障碍发生率降低到3.8%，运动功能区胶质瘤术后癫痫发生率由26.7%降至16.1%，3年生存率提高至22%。

关键词: 脑胶质瘤, 分子分型, 诊断, 治疗

Abstract: Glioma, the most common primary intracranial malignant tumor, is characterized by high disability rate, high incidence of seizure, diverse treatment response and poor survival, keeping as one of the most incurable cancers. Leading by professor Tao Jiang, this program established the new diagnosis and treatment system by building China Glioma Multi-omics database, new standard for molecular diagnosis, classification and treatment, precisive surgical techniques. By applying this program, the gross total resection rate of gliomas in functional areas has increased to 67%, long-term dysfunction rate reduced to 3.8%. The post-operative seizure rate of gliomas in motor functional areas has reduced from 26.7% to 16.1% and the 3-year survival has increased to 22%.

Key words: brain glioma, molecular classification, diagnosis, treatment

中图分类号:

R739.41

张传宝, 江涛. 脑胶质瘤诊疗关键技术创新与推广应用——2017年度国家科学技术进步二等奖[J]. 首都医科大学学报, 2018, 39(1): 1-5.

Zhang Chuanbao, Jiang Tao. The Second Grade National Prize for Science and Technology Progress——the innovation and application of key technologies in the diagnosis and treatment of brain glioma[J]. Journal of Capital Medical University, 2018, 39(1): 1-5.

参考文献

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30.
[2] Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas[J]. Cancer Lett, 2016, 375(2):263-273.
[3] Stupp R, Hegi M E, Mason W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5):459-466.
[4] Zhang W, Zhang J, Yan W, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme[J]. Cancer, 2013, 119(4):814-824.
[5] Zhang W, Qiu X G, Chen B S, et al. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas:analysis of the response and core pathway aberrations[J]. Chin Med J (Engl), 2009, 122(11):1250-1254.
[6] Wang Y, Li S, Chen L, et al. Glioblastoma with an oligodendroglioma component:distinct clinical behavior, genetic alterations, and outcome[J]. Neuro Oncol, 2012, 14(4):518-525.
[7] Zhang W, Zhang J, Hoadley K, et al. miR-181d:a predictive glioblastoma biomarker that downregulates MGMT expression[J]. Neuro Oncol, 2012, 14(6):712-719.
[8] Yang P, Zhang W, Wang Y, et al. IDH mutation and MGMT promoter methylation in glioblastoma:results of a prospective registry[J]. Oncotarget, 2015, 6(38):40896-40906.
[9] Sun Y, Zhang W, Chen D, et al. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA[J]. Proc Natl Acad Sci U S A, 2014, 111(9):3538-3543.
[10] 杨沛, 王永志, 张传宝, 等. 含少突成分胶质母细胞瘤术后治疗的卫生经济学研究[J]. 中国微侵袭神经外科杂志, 2015, 20(2):77-79.
[11] Shi Z, Zhang J, Qian X, et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression[J]. Cancer Res, 2013, 73(17):5519-5531.
[12] Bao Z S, Chen H M, Yang M Y, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas[J]. Genome Res, 2014, 24(11):1765-1773.
[13] Zhang W, Lin Y, Chen B, et al. Recurrent glioblastoma of childhood treated with bevacizumab:case report and molecular features[J]. Childs Nerv Syst, 2010, 26(1):137-143.
[14] Wang J, Fan L, Wang Y, et al. Determination of the posterior boundary of Wernicke's area based on multimodal connectivity profiles[J]. Hum Brain Mapp, 2015, 36(5):1908-1924.
[15] Wang X, Wang Y Y, Jiang T, et al. Direct evidence of the left caudate's role in bilingual control:an intra-operative electrical stimulation study[J]. Neurocase, 2013, 19(5):462-469.
[16] Li S W, Wang J F, Jiang T, et al. Preoperative 3T high field blood oxygen level dependent functional magnetic resonance imaging for glioma involving sensory cortical areas[J]. Chin Med J (Engl), 2010, 123(8):1006-1010.
[17] Xie J, Chen X Z, Jiang T, et al. Preoperative blood oxygen level-dependent functional magnetic resonance imaging in patients with gliomas involving the motor cortical areas[J]. Chin Med J (Engl), 2008, 121(7):631-635.
[18] Tian L, Jiang T, Liang M, etal. Stabilities of negative correlations between blood oxygen level-dependent signals associated with sensory and motor cortices[J]. Hum Brain Mapp, 2007, 28(7):681-690.
[19] Pu S, Li Y N, Wu C X, et al. Cortical areas involved in numerical processing:anintraoperative electrostimulation study[J]. Stereotact Funct Neurosurg, 2011, 89(1):42-47.
[20] Wu C X, Pu S, Lin Y, et al. Fractionated resection on low grade gliomas involving Broca's area and insights to brain plasticity[J]. Chin Med J (Engl), 2008, 121(20):2026-2030.
[21] Zhang Z, Jiang T, Xie J, et al. Surgical strategies for glioma involving language areas[J]. Chin Med J (Engl), 2008, 121(18):1800-1805.
[22] Huang L, You G, Jiang T, et al. Correlation between tumor-related seizures and molecular geneticprofile in 103 Chinese patients with low-grade gliomas:a preliminary study[J]. J Neurol Sci, 2011, 302(1-2):63-67.
[23] Ma R, Yan W, Zhang G, et al. Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype[J]. PLoS One, 2012, 7(6):e38096.
[24] You G, Huang L, Yang P, et al. Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas[J]. Eur J Neurol, 2012, 19(2):298-306.
[25] You G, Sha Z Y, Yan W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas:a clinicopathological study[J]. Neuro Oncol, 2012, 14(2):230-241.
[26] You G, Yan W, Zhang W, et al. Significance of miR-196b in tumor-related epilepsy of patients with gliomas[J]. PLoS One, 2012, 7(9):e46218.
[27] You G, Feng L, Yan W, et al. BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas[J]. CNS Neurosci Ther, 2013, 19(11):882-888.
[28] Wang Y, Fan X, Zhang C, et al. Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes:a quantitative analysis of glioblastomas[J]. Neuroradiology, 2014, 56(12):1113-1120.
[29] Yang P, You G, Zhang W, et al. Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas:a report of 198 patients from China[J]. Seizure, 2014, 23(10):844-851.
[30] Wang Y, Fan X, Zhang W, et al. Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy:a whole transcriptome sequencing analysis[J]. J Neurooncol, 2015, 121(3):609-616.
[31] Wang Y, Qian T, You G, et al. Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping[J]. Neuro Oncol, 2015, 17(2):282-288.
[32] Fan X, Wang Y Y, Zhang C B, et al. Expression of RINT1 predicts seizure occurrence and outcomes inpatients with low-grade gliomas[J]. J Cancer Res Clin Oncol, 2015, 141(4):729-734.
[33] 王引言, 毛庆, 王江飞, 等. 低级别胶质瘤占位效应与术后癫痫缓解率的相关性研究[J]. 中华神经外科杂志, 2014,30(10):1031-1034.